Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | C/O DENNIS M. LANFEAR 201 REDWOOD SHORES PARKWAY, SUITE 200 REDWOOD CITY CA 94065 |
Tel: | N/A |
Website: | https://www.coherus.com |
IR: | See website |
Key People | ||
Dennis M. Lanfear Chairman of the Board, President, Chief Executive Officer | Bryan Mcmichael Interim Chief Financial Officer | Theresa M. Lavallee Chief Development Officer | Paul Reider Chief Commercial Officer |
Business Overview |
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira. |
Financial Overview |
For the fiscal year ended 31 December 2023, Coherus Biosciences Inc revenues increased 22% to $257.2M. Net loss decreased 18% to $237.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development decrease of 49% to $91.2M (expense), Loss on debt extinguishment decrease from $6.2M (expense) to $0K. |
Employees: | 306 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $604.12M as of Dec 31, 2023 |
Annual revenue (TTM): | $257.24M as of Dec 31, 2023 |
EBITDA (TTM): | -$189.41M as of Dec 31, 2023 |
Net annual income (TTM): | -$237.89M as of Dec 31, 2023 |
Free cash flow (TTM): | -$175.17M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $356.69M as of Dec 31, 2023 |
Shares outstanding: | 113,498,415 as of Apr 9, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |